News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- Health Screenings Set to Start Monday
- Pharmaceutical Companies Offer Financial Support t...
- Duke University Breaks Ground on New Comprehensive...
- November is Lung Cancer Awareness Month
- Mesothelioma Tissue Banks Offer Researchers a Plac...
- Reduction of Power Plant Emissions Helpful for Low...
- NIH Award Recipient to Focus on Innovative Cancer ...
- Leading Mesothelioma Researcher Now Leads the Canc...
- $2.25 Million Awarded in Mesothelioma Death
- U.S. and China Companies Join Forces in Manufactur...
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
- December 2009
- January 2010
- February 2010
- March 2010
Monday, November 16, 2009
Prometheus Laboratories Inc, a pharmaceutical company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care, launched its ProOnc line of cancer diagnostics in October.The ProOnc diagnostic tests are based on recently developed, highly sensitive microRNA technology. “MicroRNAs are small, non-coding sequences of RNA that are critically important in many biological and pathological processes,” said Harvey Pass, M.D., Professor of Cardiothoracic Surgery and Director of the Division of Thoracic Surgery and Thoracic Oncology at New York University Langone Medical Center and its NYU Cancer Institute. The sensitivity of microRNA diagnostics enables physicians to more confidently differentiate cancers.
The ProOnc MesotheliomaDx utilizes cutting-edge molecular diagnostics using microRNA to differentiate malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.
Prometheus believes that ProOnc TumorSourceDx and ProOnc SquamousDx, as well as ProOnc MesotheliomaDx, will provide cancer specialists with more objective and quantitative results than existing diagnostics leading to more personalized treatments for patients.
Prometheus Laboratories Diagnostic Tests
Labels: mesothelioma, Treatment News
posted by Nancy Meredith at 3:16 PM
